Anda di halaman 1dari 11

Active Protocols within the Clinical Trials Operations Division at McGill University.

The
protocols are listed by disease site.

Referal is ONLY by physician consultation sent to any of the physicians based at the
McGill University Hospitals.

SITE BRAIN Investigator


Sub-Cat GLIOBLASTOMA
RTOG0420 A PHASE II STUDY OF RADIATION THERAPY LUIS SOUHAMI
PLUS LOW DOSE TEMOZOLOMIDE
FOLLOWED BY TEMOZOLOMIDE PLUS
IRINOTECAN FOR GLIOBLASTOMA
MULTIFORME

SITE BREAST Investigator


Sub-Cat
MCG0419 CHARTING THE COURSE OF ARM ANNA TOWERS
MORBIDITY IN BREAST CANCER: A
PROSPECTIVE, LONGITUDINAL FOLLOW-UP
MCG0420 A Randomized, Open-Label, Phase III Study of LAWRENCE
RPRlO98811V Every 3 Weeks Versus PANASCI
Capecitabine (Xeloda®) Tablets Twice Daily for
2 Weeks in 3-Week Cycles in Patients with
Metastatic Breast Cancer Progressing after
Taxanes and Anthracycline Therapy
NCICMA.20 A Phase III Study of Regional Radiation Therapy CHRISTINE
in Early Breast Cancer LAMBERT
RTOG9804 Phase III Trial of Tamoxifen Alone vs. Tamoxifen CHRISTINE
Plus RT for Good Risk Duct Carcinoma In-Situ LAMBERT
(DCIS) of the Female Breast
Sub-Cat ADVANCED
MCG0327 A Phase III Trial of Novel Epothilone BMS- WILSON MILLER
247550 Plus Capecitabine Versus Capecitabine
Alone in Patients with Advanced Breast Cancer
Previously Treated with an Anthracycline
MCG0402 A randomized, double blind, multicenter study to LAWRENCE
compare the efficacy and tolerability of PANASCI
fulvestrant (Faslodex) vs. Exemestane
(Aromasin) in postmenopausal women with
hormone receptor positive advanced breast
cancer with disease progression after prior non-
steroidal aromatase.
Sub-Cat METASTATIC
CR0311GSK A Randomized, Multicenter, Double-Blind, VICTOR COHEN
Placebo-Controlled, 2-Arm, Phase III Study of
Oral GW572016 in Combination with Paclitaxel
in Subjects Previously Untreated for Advanced
or Metastatic Breast Cancer (Protocol EGF3001)
*ACCRUAL AT JGH ONLY*
CR0312GSK A Randomized, Multicenter, Double-Blnd, VICTOR COHEN
Placebo-Controlled, 2-Arm, Phase III Study
Comparing GW572016 and Letrozole versus
Letrozole in Subjects with
Estrogen/Progesterone Receptor-Positive
Advanced or Metastatic Breast Cancer (protocol
EGF3008) *ACCRUAL AT JGH ONLY*
CR0503RE A Phase II Study of KOS-862 (Epothilone D), WILSON MILLER
Administered Intravenously Weekly for 3 Weeks
Every 4 Weeks, in Patiets with Metastatic Breast
Carcinoma *Open to Accrual at JGH only*
MCG0228 Phase II Trial of Caelyx and Cyclophosphamide LAWRENCE
in Metastatic Breast Cancer. PANASCI
MCG0401 A Phase 3 Randomized, Open-Label, LUIS SOUHAMI
COmparative Study of Standard WHoe Brain
Radiation Therapy wiith Supplemental Oxygen,
With ir Without Concurrent RSR13 (efaproxiral),
in Women with Brain Metastases from Breast
Cancer

SITE GI Investigator
Sub-Cat BILIARY
MCG0413 A Phase 3 Multicenter, Single-Blind, PETER KAVAN
Randomized Study of XL119 Versus 5-
Fluorouracil (5-FU) plus Leucovorin (LV) in
Subjects with Advanced Biliary Tumors Not
Amenable to Conventional Surgery
Sub-Cat COLORECTAL
MCG0306 An Open-Label, Randomized Phase III Study of RICHARD DALFEN
Intermittent Oral Capecitabine in Combination
with Intravenous Oxaliplatin (Q3W) ("Xelox")
Versus Bolus and Continuous Infusion
Fluorouracil/Intravenous Leucovorin with
Intravenous Oxaliplatin (Q2W) ("FOLFOX") as
Second-Line Treatment for Patients with
Metastatic Colorectal Cancer who have
Received Prior CPT-11 Plus 5-FU+LV as First
Line Therapy.
MCG0325 A RANDOMIZED, DOUBLE-BLIND, PLACEBO- WILSON MILLER
CONTROLLED, PHASE III STUDY IN
PATIENTS WITH METASTATIC
ADENOCARCINOMA OF THE COLON OR
RECTUM WHO ARE RECEIVING FIRST-LINE
CHEMOTHERAPY WITH OXALIPLATIN/5-
FLUOROURACIL/LEUCOVORIN AND
PTK787/222584
MCG0412 An Exploratory Pharmacogenomic Study of MARK BASIK
Erbitux Monotherapy in Patients with Metastatic
Colorectal Carcinoma *On-Hold at MGH. Please
refer patients to Dr. Basik at JGH*
MCG0429 Phase II Study of Neoadjuvant 5- PETER METRAKOS
FU+Leucovorin+CPT-11 in Patients with Liver
Metastases From Colorectal Adenocarcinoma.
MCG0503 First-Line Bevacizumab and Chemotherapy in GERALD BATIST
Metastatic Cancer of the Colon or Rectum: First
Beat (Bevacizumab Expanded Access Trial)
NCICCO.17 A Phase III Randomized Study of Erbitux RICHARD DALFEN
(Cetucimab C225) and Best Supportive Care
Versus Best Supportive Care in Patients with
Pretreated Metastatic Epidermal Growth Factor
Receptor-Positive Colorectal Carcinoma
Sub-Cat PANCREAS
NCICPA.2 Phase III Adjuvant Trial in Pancreatic Cancer WILSON MILLER
Comparing (1) 5-FU and D-L Folinic Acid Versus
(2) Gemcitabine Versus (3) No Adjuvant
Treatment
Sub-Cat RECTAL
MCG0211 A Phase II Study of Using IMRT Radiation for TE VUONG
Patients with Unresectable Recto Sigmoid
Cancer
MCG0324 A Phase I/II Study of Using Pre-Operative High TE VUONG
Dose Rate Brachytherapy for Patients with
Advanced Lower Rectal Cancer in Preparation
for Sphincter Preservation Surgery.
RTOG0315 A Randomized Double Blind, Placebo Controlled LORRAINE
Phase III Study to Determine the Efficacy of PORTELANCE
Sandostatin LAR Deport (Octreotide Acetate) in
Preventing or Reducing the Severity of
Chemoradiation-Induced Diarrhea in Patiets with
Anal or Rectal Cancer
RTOG9811 A Phase III Randomized Study of 5-Fluorouracil, TE VUONG
Mitomycin-C, and Radiotherapy versus 5-
Fluorouracil, Cisplatin, and Radiotherapy in
Carcinoma of the Anal Canal

SITE GU Investigator
Sub-Cat BLADDER
NCICBL.8 Randomized Phase III Trial Comparing RAGHU RAJAN
Immediate Versus Deferred Chemotherapy After
Radical Cystectomy in Patients with pT3-pT4,
and/or N + M0 Transitional Cell Carcinoma
(TCC) of the Bladder
RTOG0233 A Phase II Randomized Trial for Paitnets with LUIS SOUHAMI
Muscle-Invading Bladder Cancer Evaluating
Transurethral Surgery and BID Irradiation Plus
Either Paclitaxel and Cisplatin or 5-Fluorouracil
and Cisplatin Followed by Selective Bladder
Preservation and
Gemcitabine/Paclitaxel/Cisplatin Adjuvant
Chemotherapy.
Sub-Cat PROSTATE
NCICPR.3 Intergroup (NCIC CTG, CUOG, and ECOG) LUIS SOUHAMI
Phase III Randomized Trial Comparing Total
Androgen Blockade versus Total Androgen
Blockade plus Pelvic Irradiation in Clinical Stage
T3-4, NO, MO Adenocarcinoma of the Prostate
NCICPR.8 Intermittent Androgen Deprivation in Patients RAGHU RAJAN
with Stage D2 Prostate Cancer, Phase III Study
RTOG0215 Treatment of Erectile Dysfunction in Patients MARIE DUCLOS
Treated on RTOG 9910 for Prostate Cancer:
Impact on Patients and Partner Quality of Life.
RTOGP-0126 A Phase III Randomized Study of High Dose 3D- MARIE DUCLOS
CRT Versus Standard Dose 3D-CRT in Patients
Treated for Localized Prostate Cancer.

SITE GYNECOLOGY Investigator


Sub-Cat
NCICGT.1 Randomized Phase III Trial of Weekly GERRY STANIMIR
Parenteral Methotrexate Versus "Pulsed"
Dactinomycin as Primary Management for Low
Risk Gestational Trophoblastic Neoplasia
Sub-Cat CERVIX
MCG0201 A PHase I/II Study to Evaluate the Safety and LUIS SOUHAMI
Tolerance of RSR13 Administered to Patients
Receiving a Course of Cisplatin and Radiation
Therapy for Locally Advanced Carcinoma of the
Cervix
RTOG0116 A Two Part Phase I/II Study of Extended Field LORRAINE
External Irradiation and Intracavitary PORTELANCE
Brachytherapy Combined With Chemotherapy
(Weekly Cisplatin - Arm 1) and Amifostine
(Weekly Cisplatin and Amifostine - Arm 2) in
Carcinoma of the Cervix With Positive Para-
Aortic or High Common Iliac Lymph Nodes
Sub-Cat ENDOMETRIUM
NCICIND.160 A PHASE II STUDY OF CCI-779 IN PATIENTS LAWRENCE
WITH METASTATIC AND/OR LOCALLY PANASCI
ADVANCED RECURRENT ENDOMETRIAL
CANCER
Sub-Cat OVARIAN
MCG0332 Phase II, Open-Label Study of CAELYX and WILSON MILLER
Carboplatin in Platinum-Sensitive Relapsed
Epithelial Ovarian Cancer
NCICOV.13 An International Multi-Centre Randomized GERRY STANIMIR
Phase III Study Comparing Upfront Debulking
Surgery Versus Neo-Adjuvant Chemotherapy in
Patients with Stage IIIC or IV Epithelial Ovarian
Carcinoma

SITE HEAD & NECK Investigator


Sub-Cat
CR0415GS A Randomized Trial Comparig Preservation of
Function Status After Either Medpulser
Electroporation with Intratumoral Bleomycin
Therapy or Surgery in Patients with Locally
Recurrent or Second Primary Squamous Cell
Carcinoma of the Anterior Oral Cavity, Soft
Palate, and Tonsil that Have Failed Primary
Curative Therapy *ACCRUAL AT JGH ONLY*
CR0416GS A Randomized Trial Comparing Preservation of
Function Status After Either Medpulser
Electroporation with Intratumoral; Bleomycin
Therpay or Surgery in Patients with Locally
Recurrent or Second Primary Squamous Cell
Carcinoma of the Base of Tongue, Posterior
Lateral Pharyngeal Wall, Hypopharynx and
Larynx ThatHave Failed Primary Curative
Therapy *ACCRUAL AT JGH ONLY*
MCG0329 1839IL/0704 - A PHASE III RANDOMISED, MICHAEL POLLAK
STRATIFIED, PARALLEL-GROUP, MULTI-
CENTRE, COMPARATIVE STUDY OF ZD1839
(IRESSA) 250 MG AND 500 MG VERSUS
METHOTREXATE FOR PREVIOUSLY
TREATED PATIENTS WITH SQUAMOUS CELL
CARCINOMA OF THE HEAD AND NECK
(IMEX).
Sub-Cat ADVANCED
MCG0212 A Phase III Randomized Trial of Concomitant GEORGE
Radiation, Cisplatin and Tirapazamine Versus SHENOUDA
Concomitant Radiation and Cisplatin in Patients
with Advanced Head and Neck Cancer
RTOG0234 A Phase II Randomized Trial of Surgery
Followed by Chemoradiotherapy Plus C225
(Cetuximab) for Advanced Squamous Cell
Carcinoma of the Head and Neck
RTOGH- A Phase III Trial of Concurrent Radiation and KHALIL SULTANEM
0129 Chemotherapy for Advanced Head and Neck
Carcinomas.
SITE HEMATOLOGY Investigator
Sub-Cat AML
MCG0309 A Multicenter, Double-Blind, Randomized, PIERRE
Phase 2 Trial Comparing Pegfilgrastim with LANEUVILLE
Filgrastim as an Adjucnt to Chemotherapy for
Acute Myeloid Leukemia.
Sub-Cat CLL
CR0407LG Multicenter, Phase II Study of ONTAK WILSON MILLER
(Denileukin Diftitox) in Patients with Previously
Treated Chronic Lymphocytic Leukemia
*ACCRUAL AT JGH ONLY*
CR0408LG Multicenter, Phase II Study of ONTAK WILSON MILLER
(Denileukin diftitox) in Patients with Previously
Treated Chronic Lymphocytic Leukemia
*ENROLLMENT AT JGH ONLY*
MCG0204 Randomized Study of Fludarabine and CHAIM SHUSTIK
Cyclophosphamide with or without Genasense
(Bcl-2 Antisense Oligonucleotide) in Patients
with Relapsed or Refractory Chronic
Lymphocytic Leukemia.
MCG0317 AN OPEN LABEL MULTICENTER, CHAIM SHUSTIK
RANDOMIZED COMPARATIVE, PHASE III
STUDY TO EVALUATE THE EFFICACY AND
SAFETY OF RITUXIMAB PLUS FLUDARABINE
AND CYCLOPHOSPHAMIDE (FCR) VERSUS
FLUDARABINE AND CYCLOPHOSPHAMIDE
ALONE (FC) IN PREVIOUSLY TREATED
PATIENTS WITH CD20 POSTIVE B-CELL
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Sub-Cat CML
MCG0426 A Phase II Study of BMS-354825 in Subjects CARLO
With Accelerated Phase Chronic Myeloid GAMBACORTI
Leukemia Resistant to or Intolerant of Imatinib
Mesylate
MCG0427 A Phase II Study of BMS-354825 in Subjects PIERRE
With Myeloid Blast Phase Chronic Myeloid LANEUVILLE
Leukemia Resistant to or Intolerant of Imatinib
Mesylate
MCG0428 A Phase II Study of BMS-354825 in Subjects PIERRE
With Lymphoid Blast Phase Chronic Myeloid LANEUVILLE
Leukemia or Philadelphia Chromosome Positive
Acute Lymphoblastic Leukemia Refractory to or
Intolerant of Imatinib Mesylate
MCG0431 AN OPEN-LABEL, RANDOMIZED, PIERRE
MULTICENTRE STUDY COMPARING LANEUVILLE
GLEEVEC (IMATINIB) AT DOSES OF 400MG
AND 800MG IN OBTAINING MAJOR
MOLECULAR RESPONSE IN CHRONIC
PHASE PATIENTS WITH PHILADELPHIA
CHROMOSOME POSITIVE CHRONIC
MYELOGENOUS LEUKEMIA THAT HAVE
REACHED A COMPLETE CYTOGENETIC
RESPONSE DURING 400MG ON GLEEVEC
(IMATINIB)"
MCG0432 A Phase II Study to Determine the Activity of CARLO
BMS-354825 in Subjects With Chronic Phase GAMBACORTI
Philadelphia Chromosome Positive Chronic
Myelogenous Leukemia Who Have Disease
That is Resistant to High Dose Imatinib Mesylate
(Gleevec®) or Who Are Intolerant of Imatinib
MCG0433 A Randomized Multi-Center Open Label Study CARLO
of BMSs-354825 Vs Imatinib Mesylate GAMBACORTI
(Gleevec®) 800 Mg/D in Subjects With Chronic
Phase Philadelphia Chromosome Positive
Chronic Myeloid Leukemia Who Have Disease
That is Resistant to Imatinib at a Dose at 400 -
600 Mg/D
Sub-Cat HODGKIN'S
NCICHD.7 A Randomized Phase III Trial of ABVD Versus SILVY LACHANCE
Stanford V+/- Radiation Therapy in Locally
Extensive and Advanced Stage Hodgkin's
Disease with 0-2 Risk Factors
Sub-Cat LYMPHOMA
RTOG0227 Phase I/II Study of Pre-Irradiation CHRISTINE
Chemotherapy with Methotrexate, Rituximab LAMBERT
and Temozolomide and Post-Irradiation
Temozolomide for Primary Central Nervous
System Lymphoma
Sub-Cat MYELOMA
NCICMY.10 A Randomized Phase III Study of Thalidomide CHAIM SHUSTIK
and Prednisone Versus no Further Therapy as
Mainenance Following Autologous Stme Cell
Transplant in Patients with Multiple Myeloma
Sub-Cat NHL
CR9910LD A Multicenter, Open-Label Study to Evaluate the WILSON MILLER
Safety and Efficacy of DAB389IL-2 in Cutaneous
T-cell Lymphoma (CTCL) Patients Following
Protocol 93-04-10, Protocol 93-04-11, or
Protocol 92-04-01 or who Meet the
Requirements for Protocol 93-04-11 Except
Have Biopsy-Documented CTCL That Does Not
Express CD25 *ACCRUAL AT JGH ONLY*
CR9911LD A Multicenter Phase III Randomized Double- WILSON MILLER
Blind Placebo Controlled Study to Evaluate the
Efficacy of Two Dose Levels of DAB389IL-2 (9
and 18ug/kg/day) in Cutaneous T-Cell
Lymphoma (CTCL) Patients with Stage Ia-III
Disease who Following <3 Previous Therapies
Have Recurrent or persisitant Disease that has
been Biopsy-Documented to Express CD25
*ACCRUAL AT JGH ONLY*

SITE LUNG Investigator


Sub-Cat BRAIN METS
MCG0223 Randomized Phase III Trial of Xcytrin (Motexafin LUIS SOUHAMI
Gadolinium) Injection for the Treatment of Brain
Metastases in Patients with Non-Small Cell Lung
Cancer Undergoing Whole-Brain Radiation
Therapy
MCG0320 A randomized double-blind placebo controlled LUIS SOUHAMI
phase 3 study of temozolomide or placebo
added to whole brain radiation therapy for the
treatment of brain metastases from non-small
cell lung cancer.
RTOG0320 A Phase III Trial Comparing Whole Brain DAVID ROBERGE
Radiation and Stereotactic Radiosurgery ALone
Versus with Temozolomide or Geftinib in
Patients with Non-Small Cell Lung Cancer and
1-3 Brain Metastases
Sub-Cat NSCLC
CR0501PR A Phase Ib Dose Escalation/Phase 2 HARVEY KREISMAN
Randomized, Non-Comparative, Multiple Center,
Open-Label Study of CP-751,871 in
Combination with Paclutaxel and Carboplatin
and of Paclitace; amd Carboplatin Alone as First
Line Treatment for Advanced Non-Small Cell
Lung Cancer *Open to Accrual at JGH only*
MCG0005 Multicenter, Open-Ended, Double-Blind, GERRY BATIST
Placebo-Controlled, Phase III Study of AE-941
in addition to Combined Modality Treatment
(Chemotherapy/Radiotherapy) for Locally
Advanced Unresectable Non-Small Cell Lung
Cancer
MCG0110 Phase I/II Multicenter Trial with Carboplatin and VERA HIRSH
Gemcitabine Induction Chemotherapy, Followed
by Radiotherapy Concomitantly with Low-Dose
Weekly Paclitaxel and Gemcitabine for Patients
with Stage IIIA + B Non-Small Cell Lung Cancer
MCG0318 Randomized, Placebo-Controlled, Double-Blind, VERA HIRSH
Phase 2 Study of Gemcitabine-Cisplatin
Combined with Two Different Doses of LY29311
or Placebo in Patients with Stage IIIB or IV Non-
Small Cell Lung Cancer.
MCG0404 A RANDOMIZED OPEN-LABEL PHASE II VERA HIRSH
STUDY OF ZD1839 (IRESSA) VERSUS
GEMCITABINE AND CARBOPLATIN IN
CHEMOTHERAPY-NAIVE PATIENTS WITH
ADVANCED (STAGE IIIB OR IV) NON-SMALL
CELL LUNG CANCER AND ECOG
PERFORMANCE STATUS 2
MCG0410 A RANDOMISED, OPEN-LABEL, PARALLEL VERA HIRSH
GROUP, INTERNATIONAL MULTICENTER,
PHASE III STUDY OF ORAL ZD1839 (IRESSA)
VERSUS INTRAVENOUS DOCETAXEL
(TAXOTERE) IN PATIENTS WITH LOCALLY
ADVANCED OR METASTATIC RECURRENT
NON-SMALL CELL LUNG CANCER WHO
HAVE PREVIOUSLY RECEIVED PLATINUM-
BASED CHEMOTHERAPY
MCG0417 A PROSPECTIVE, MULTICENTER, VERA HIRSH
RANDOMIZED, PHASE II STUDY TO
EVALUATE THE EFFECTS OF ZOMETA IN
COMBINATION WITH
TAXOTERE/CARBOPLATIN IN PATIENTS
WITH STAGE IIIB/IV UNRESECTABLE NON-
SMALL CELL LUNG CANCER
MCG0423 A Randomized, Double-Blind Multicenter 2- VERA HIRSH
Stage Phase III Study of Bevacizumab in
Combination with Cisplatin and Gemcitabine
versus Placebo, Cisplatin and Gemcitabine in
Patients with Advanced or Recurrent Non-
Squamous Non-Small Cell Lung Cancer, Who
Have Not Received Prior Chemotherapy.
NCICBR.16 Phase III Chemoprevention Trial of Selenium JAMES GRUBER
Supplementation in Patients with Resected
Stage I Non-Small Cell Lung Cancer
RTOGL-0127 Phase III Chemoprevention Trial of Selenium KHALIL SULTANEM
Supplementation in Persons with Resected
Stage I Non-Small Cell Lung Cancer
RTOGL-0214 A Phase III Comparison of Prophylactic Cranial L PORTELANCE
Irradiation Versus Observation in Patients with
Locally Advanced Non-Small Cell Lung Cancer
Sub-Cat SCLC
CR0306PR A Phase II Multicenter, Open-Label, Clinical and WILSON MILLER
Pharmacokinetic Study of Aplidin (APL) as a 1-
Hour Weekly Infusion, in Patients with Small Cell
Lung Carcinoma, Relapsing or Progressing After
First-Line Chemotherapy *ACCRUAL AT JGH
ONLY*
NCICBR.20 A Phase II Study of ZD6474 or Placebo in Small VERA HIRSH
Cell Lung Cancer Patients who have Complete
or Partial Response to Induction Chemotherapy
+ Radiation Therapy
RTOG0212 A Phase II/III Randomized Trial of Two Doses SERGIO FARIA
(Phase III-Standard vs High) and Two High
Dose Schedules (Phase II-Once vs Twice Daily)
for Delivering Prophylactic Cranial Irradiation for
Patients with Limited Disease Small Cell Lung
Cancer

SITE MALIGNANCY Investigator


Sub-Cat
CR0412MR Phase I-II Trial of Intravenous Ascorbic Acid in J. HOFFER
Patiets with Incurable Malignancies *Open to
Accrual at JGH only*

SITE MELANOMA Investigator


Sub-Cat
CR0406CX A Phase III Randomized, Double-Blind Trial of WILSON MILLER
Immunotherapy with a Polyvalent Melanoma
Vaccine, CancerVax Vaccine Plus BCG versus
Placebo plus BCG as a Post-Surgical Treatment
for Stage IV Melanoma *ACCRUAL AT JGH
ONLY*
CR0409BX First Administration of Dendric Cells Transduced FRANCOIS
with Immunovex tri-melan to Patiebts with PATENAUDE
Metastatic or Inoperable Melanoma; Prelimiary
Assessment of Safety, Biodistribution and
Indicators of Efficacy. * OPEN TO ACCRUAL AT
JGH ONLY *
NCICME.10 Phase III Randomized Study of Four Weeks FRANCOIS
High Dose IFN- 2b in Stage II-A Melanoma PATENAUDE

SITE SOLID TUMORS Investigator


Sub-Cat
CR0410ON A Phase I Study of AEG35156/GEM640 and GERALD BATIST
Docetaxel Given Once Every Three Weeks in
Patients with Solid Tumors *Open to Accrual at
JGH only*
CR0414CR Phase I Study of CPX-1 (Irinotecan HCL: GERALD BATIST
Floxuridine) Liposome Injection in Patiets with
Advanced Solid Tumors *ACCRUAL AT JGH
ONLY*

SITE SYMPTOM CONT Investigator


Sub-Cat
CR0401AB A Phase III Randomized Study Comparing Oral KHALIL SULTANEM
Pilocarpine vs. Submandibular Salivary Gland
Transfer Protocol for the Prevention of Radiation
Induced Xerostomia *ACCRUAL AT JGH ONLY*
CR0404WX A Multicentre, Randomized, Double-Blund, B LAPOINTE
Placebo-COntrolled, Parallel-Design Trial of the
Efficacy and Safety of Subcutaneous
Tetrodotoxin (Tectin) for Moderate to Severe
Inadequately Cancer-Related Pain. (WEX 014)
*ACCRUAL AT JGH ONLY*
MCG0308 A Phase III Multi-Center, Double-Blind, BRUNO GAGNON
Randomized, Placebo-Controlled, Parallel-
Group, Dose-Titration Study of Imidapril
Hydrochloride (EG006) in the Treatment of
Cancer Cachexia.
MCG0314 IMN1207 Versus Casein in the Prevention of NEIL MACDONALD
Wasting Over Six Months During, or Following
Chemotherapy, Radiation or Surgery in the
Treatment of Colorectal or Non-Small Cell Lung
Cancer: A Multicenter, Randomized, Double-
Blind Study.
MCG0406/07 Prognostic Value Of The Genetic And Biologic ANTONIO VIGANO
Determinants Of Inflammation In Cancer
Cachexia: A Pilot Study
NCICSC.20 A Phase III Interational Randomized Trial of MARC DAVID
Single Versus Multiple Fractions for Re-
Irradiation of Painful Bone Metastases

Please contact the Clinical Research Program or at (514) 398-8907, for more information.